Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Atletico Madrid

Under threat: The pharma industry in Spain

The Eurozone crisis threatens healthcare and pharma opportunities

- PMLiVE

UCB’s chair Gerhard Mayr joins Almirall board

He becomes an independent director of the Spanish pharma company

Eisai’s epilepsy drug Fycompa gets green light in US

Japanese firm predicts global sales of more than $1bn at peak

- PMLiVE

Amgen’s Anna Richo joins UCB as executive VP and general counsel

Meanwhile, Cynthia Patton takes over as Amgen’s senior VP and chief compliance officer

- PMLiVE

VIDEO: Eisai manufacturing plans shows UK is recovering from ‘shock’ of Pfizer/AZ cutbacks

David Willetts says life sciences industry has future in UK at opening of Fycompa manufacturing site

- PMLiVE

Communications effectiveness – what are we really measuring?

When pharma clients demand more effectiveness, do they really know what they want, asks Michel Nakache?

- PMLiVE

UCB opens biotech plant in Belgium

100 jobs created as pharma firm plans to expand its focus on biologics

Eisai launches epilepsy drug Fycompa in UK

CEO of Eisai EMEA Gary Hendler says UK “last free pricing market in Europe”

- PMLiVE

Hanover wins UCB pitch

The agency aims to raise the profile of the biopharma company

- PMLiVE

Medical communications 2.0

How social is medical communications?

- PMLiVE

Interview with Roch Doliveux, UCB

Why is patient-centricity placed at the heart of UCB? Jacky Law asked UCB’s CEO to explain his company’s philosophy

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links